Top

Published in:

Open Access 01-12-2019 | Care | Research

Is systematic fecal carriage screening of extended-spectrum beta-lactamase-producing Enterobacteriaceae still useful in intensive care unit: a systematic review

Authors: Renaud Prevel, Alexandre Boyer, Fatima M’Zali, Agnès Lasheras, Jean-Ralph Zahar, Anne-Marie Rogues, Didier Gruson

Published in: Critical Care | Issue 1/2019

Abstract

Background

Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) are disseminating worldwide leading to increased hospital length of stay and mortality in intensive care units (ICU). ESBL-E dissemination was first due to outbreaks in hospital settings which led to the implementation of systematic fecal carriage screening to improve hygiene procedures by contact precautions. ESBLs have since spread in the community, and the relevance of contact precautions is questioned. ESBL-E dissemination led to an overuse of carbapenems triggering the emergence of carbapenem-resistant Enterobacteriaceae. Empirical antimicrobial therapy based on ESBL-E fecal carriage has been proposed but is debated as it could increase the consumption of carbapenems among ESBL-E carriers without any clinical benefit. Finally, selective decontamination among ESBL-E fecal carriers is evoked to decrease the risk for subsequent ESBL-E infection, but its efficacy remains debated. We propose to systematically review the evidence to recommend or not such systematic ESBL-E fecal carriage screening in adult ICU.

Methods

Every article focusing on ESBL-E and ICU available on the MEDLINE database was assessed. Articles were included if focusing on cross-transmission, efficacy of hygiene procedures, link between ESBL-E colonization and infection or guidance of empirical therapy or selective decontamination efficacy.

Results

Among 330 articles referenced on PubMed, 39 abstracts were selected for full-text assessment and 25 studies were included. Systematic screening of ESBL-E fecal carriage to guide contact precautions do not seem to decrease the rate of ESBL-E cross-transmission. It has a very good negative predictive value for subsequent ESBL-E infections but a positive predictive value between 40 and 50% and so does not help to spare carbapenems. Cessation of ESBL-E carriage systematic screening could decrease the use of carbapenems in ICU without any clinical harm. Nevertheless, further studies are needed to validate these results from monocentric before-after study. Selective decontamination strategy applied to ESBL-E fecal carriers could be helpful, but available data are conflicting.

Conclusion

Current knowledge lacks of high-quality evidence to strongly recommend in favor of or against a systematic ESBL-E fecal carriage screening policy for ICU patients in a non-outbreak situation. Further evaluation of selective decontamination or fecal microbiota transplantation among ESBL-E fecal carriers is needed.

Available only for authorised users

Carlet J. The world alliance against antibiotic resistance: consensus for a declaration. Clin Infect Dis. 2015;60:1837–41.CrossRef

Woerther P-L, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum -lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev. 2013;26:744–58.CrossRef

Flokas ME, Alevizakos M, Shehadeh F, Andreatos N, Mylonakis E. Extended-spectrum β-lactamase-producing Enterobacteriaceae colonisation in long-term care facilities: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;50:649–56.CrossRef

Nicolas-Chanoine M-H, Gruson C, Bialek-Davenet S, Bertrand X, Thomas-Jean F, Bert F, et al. 10-fold increase (2006-11) in the rate of healthy subjects with extended-spectrum -lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre. J Antimicrob Chemother. 2013;68:562–8.CrossRef

Tansarli GS, Karageorgopoulos DE, Kapaskelis A, Falagas ME. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti-Infect Ther. 2013;11:321–31.CrossRef

Maslikowska JA, Walker SAN, Elligsen M, Mittmann N, Palmay L, Daneman N, et al. Impact of infection with extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs. J Hosp Infect. 2016;92:33–41.CrossRef

Esteve-Palau E, Solande G, Sánchez F, Sorlí L, Montero M, Güerri R, et al. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: a matched cohort study. J Inf Secur. 2015;71:667–74.

Leistner R, Gürntke S, Sakellariou C, Denkel LA, Bloch A, Gastmeier P, et al. Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort. Infection. 2014;42:991–7.CrossRef

Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20:1–55.CrossRef

10.

March A, Aschbacher R, Dhanji H, Livermore DM, Böttcher A, Sleghel F, et al. Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria. Clin Microbiol Infect. 2010;16:934–44.CrossRef

11.

Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, et al. The epidemic of extended-spectrum-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. mBio. 2013;4 Available from: http://mbio.asm.org/cgi/doi/10.1128/mBio.00377-13. [cited 2018 Oct 31].

12.

Bauernfeind A, Grimm H, Schweighart S. A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection. 1990;18:294–8.CrossRef

13.

Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control. 2007;35:S65–164.CrossRef

14.

Lowe CF, Katz K, McGeer AJ, Muller MP. For the Toronto ESBL working group. Efficacy of admission screening for extended-spectrum beta-lactamase producing Enterobacteriaceae. Kluytmans J, editor. PLoS One. 2013;8:e62678.CrossRef

15.

Société française d’hygiène hospitalière (SF2H). Prévention de la transmission croisée: précations complémentaires contact; 2009;XII. p. 81.

16.

Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal colonization with extended-spectrum beta-lactamase–producing Enterobacteriaceae and risk factors among healthy individuals: a systematic review and metaanalysis. Clin Infect Dis. 2016;63:310–8.CrossRef

17.

Armand-Lefèvre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E, et al. Emergence of imipenem-resistant Gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013;57:1488–95.CrossRef

18.

McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae. Antimicrob Agents Chemother. 2013;57:5131–3.CrossRef

19.

Bruyère R, Vigneron C, Bador J, Aho S, Toitot A, Quenot J-P, et al. Significance of prior digestive colonization with extended-spectrum β-lactamase–producing Enterobacteriaceae in patients with ventilator-associated pneumonia. Crit Care Med. 2016;44(4):699–706.

20.

Bretonnière C, Leone M, Milési C, Allaouchiche B, Armand-Lefevre L, Baldesi O, et al. Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric). Intensive Care Med. 2015;41:1181–96.CrossRef

21.

Carlet J. The gut is the epicentre of antibiotic resistance. Antimicrob Resist Infect Control. 2012;1:39.CrossRef

22.

Gori A, Espinasse F, Deplano A, Nonhoff C, Nicolas MH, Struelens MJ. Comparison of pulsed-field gel electrophoresis and randomly amplified DNA polymorphism analysis for typing extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae. J Clin Microbiol. 1996;34:2448–53.PubMedPubMedCentral

23.

Thouverez M, Talon D, Bertrand X. Control of Enterobacteriaceae producing extended-spectrum beta-lactamase in intensive care units: rectal screening may not be needed in non-epidemic situations. Infect Control Hosp Epidemiol. 2004;25:838–41.CrossRef

24.

Harris AD, Kotetishvili M, Shurland S, Johnson JA, Morris JG, Nemoy LL, et al. How important is patient-to-patient transmission in extended-spectrum β-lactamase Escherichia coli acquisition. Am J Infect Control. 2007;35:97–101.CrossRef

25.

Kim J, Lee JY, Kim SI, Song W, Kim J-S, Jung S, et al. Rates of fecal transmission of extended-spectrum β-lactamase-producing and carbapenem-resistant Enterobacteriaceae among patients in intensive care units in Korea. Ann Lab Med. 2014;34:20–5.CrossRef

26.

O’Connell N, Keating D, Kavanagh J, Schaffer K. Detection and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae in high-risk patients in an Irish tertiary care hospital. J Hosp Infect. 2015;90:102–7.CrossRef

27.

Alves M, Lemire A, Decré D, Margetis D, Bigé N, Pichereau C, et al. Extended-spectrum beta-lactamase − producing enterobacteriaceae in the intensive care unit: acquisition does not mean cross-transmission. BMC Infect Dis. 2016;16 Available from: http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1489-z. [cited 2018 Oct 31].

28.

Repessé X, Artiguenave M, Paktoris-Papine S, Espinasse F, Dinh A, Charron C, et al. Epidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae in an intensive care unit with no single rooms. Ann Intensive Care. 2017;7 Available from: http://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-017-0295-0. [cited 2018 Oct 31].

29.

Derde LPG, Cooper BS, Goossens H, Malhotra-Kumar S, Willems RJL, Gniadkowski M, et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis. 2014;14:31–9.CrossRef

30.

Jalalzaï W, Boutrot M, Guinard J, Guigon A, Bret L, Poisson D-M, et al. Cessation of screening for intestinal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in a low-endemicity intensive care unit with universal contact precautions. Clin Microbiol Infect. 2018;24:429.e7–429.e12.CrossRef

31.

Renaudin L, Llorens M, Goetz C, Gette S, Citro V, Poulain S, et al. Impact of discontinuing contact precautions for MRSA and ESBLE in an intensive care unit: a prospective noninferiority before and after study. Infect Control Hosp Epidemiol. 2017;38:1342–50.CrossRef

32.

Kardaś-Słoma L, Lucet J-C, Perozziello A, Pelat C, Birgand G, Ruppé E, et al. Universal or targeted approach to prevent the transmission of extended-spectrum beta-lactamase-producing Enterobacteriaceae in intensive care units: a cost-effectiveness analysis. BMJ Open. 2017;7:e017402.CrossRef

33.

Lepape A, Machut A, Savey A. Réseau national Réa-Raisin de surveillance des infections acquises en réanimation adulte - Méthodes et principaux résultats. Méd Intensive Réanimation. 2018;27:197–203.CrossRef

34.

Razazi K, Derde LPG, Verachten M, Legrand P, Lesprit P, Brun-Buisson C. Clinical impact and risk factors for colonization with extended-spectrum β-lactamase-producing bacteria in the intensive care unit. Intensive Care Med. 2012;38:1769–78.CrossRef

35.

Liu M, Li M, Wu L, Song Q, Zhao D, Chen Z, et al. Extended-spectrum β-lactamase-producing E. coli septicemia among rectal carriers in the ICU: Medicine (Baltimore), vol. 97; 2018. p. e12445.

36.

Martins IS, Pessoa-Silva CL, Nouer SA, Pessoa de Araujo EG, Ferreira ALP, Riley LW, et al. Endemic extended-spectrum beta-lactamase-producing Klebsiella pneumoniae at an intensive care unit: risk factors for colonization and infection. Microb Drug Resist. 2006;12:50–8.CrossRef

37.

Razazi K, Mekontso Dessap A, Carteaux G, Jansen C, Decousser J-W, de Prost N, et al. Frequency, associated factors and outcome of multi-drug-resistant intensive care unit-acquired pneumonia among patients colonized with extended-spectrum β-lactamase-producing Enterobacteriaceae. Ann Intensive Care. 2017;7 Available from: http://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-017-0283-4. [cited 2018 Oct 31].

38.

Carbonne H, Le Dorze M, Bourrel A-S, Poupet H, Poyart C, Cambau E, et al. Relation between presence of extended-spectrum β-lactamase-producing Enterobacteriaceae in systematic rectal swabs and respiratory tract specimens in ICU patients. Ann Intensive Care. 2017;7 Available from: http://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-017-0237-x. [cited 2018 Oct 31].

39.

for the OUTCOMEREA Study Group, Barbier F, Bailly S, Schwebel C, Papazian L, Azoulay É, et al. Infection-related ventilator-associated complications in ICU patients colonised with extended-spectrum β-lactamase-producing Enterobacteriaceae. Intensive Care Med. 2018;44:616–26.CrossRef

40.

Houard M, Rouzé A, Ledoux G, Six S, Jaillette E, Poissy J, et al. Relationship between digestive tract colonization and subsequent ventilator-associated pneumonia related to ESBL-producing Enterobacteriaceae. Kou YR, editor. PLoS One. 2018;13:e0201688.CrossRef

41.

Barbier F, Pommier C, Essaied W, Garrouste-Orgeas M, Schwebel C, Ruckly S, et al. Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure? J Antimicrob Chemother. 2016;71:1088–97.CrossRef

42.

Brun-Buisson C, Legrand P, Rauss A, Richard C, Montravers F, Besbes M, et al. Intestinal decontamination for control of nosocomial multiresistant gram-negative bacilli. Study of an outbreak in an intensive care unit. Ann Intern Med. 1989;110:873–81.CrossRef

43.

Troché G, Joly L-M, Guibert M, Zazzo J-F. Detection and treatment of antibiotic-resistant bacterial carriage in a surgical intensive care unit: a 6-year prospective survey. Infect Control Hosp Epidemiol. 2005;26:161–5.CrossRef

44.

Camus C, Sauvadet E, Tavenard A, Piau C, Uhel F, Bouju P, et al. Decline of multidrug-resistant Gram negative infections with the routine use of a multiple decontamination regimen in ICU. J Inf Secur. 2016;73:200–9.

45.

Decré D, Gachot B, Lucet JC, Arlet G, Bergogne-Bérézin E, Régnier B. Clinical and bacteriologic epidemiology of extended-spectrum beta-lactamase-producing strains of Klebsiella pneumoniae in a medical intensive care unit. Clin Infect Dis. 1998;27:834–44.CrossRef

46.

Wittekamp BH, Plantinga NL, Cooper BS, Lopez-Contreras J, Coll P, Mancebo J, et al. Decontamination strategies and bloodstream infections with antibiotic-resistant microorganisms in ventilated patients: a randomized clinical trial. JAMA. 2018;320:2087.CrossRef

47.

Tacconelli E. EUCIC medical guidelines on decolonization of multidrug-resistant gram-negative organisms; 2018.

48.

Tissera K, Liyanapathirana V, Dissanayake N, Pinto V, Ekanayake A, Tennakoon M, et al. Spread of resistant gram negatives in a Sri Lankan intensive care unit. BMC Infect Dis. 2017;17:490.CrossRef

49.

Conterno LO, Shymanski J, Ramotar K, Toye B, Zvonar R, Roth V. Impact and cost of infection control measures to reduce nosocomial transmission of extended-spectrum β-lactamase-producing organisms in a non-outbreak setting. J Hosp Infect. 2007;65:354–60.CrossRef

50.

Tschudin-Sutter S, Frei R, Dangel M, Stranden A, Widmer AF. Rate of transmission of extended-spectrum beta-lactamase-producing Enterobacteriaceae without contact isolation. Clin Infect Dis. 2012;55:1505–11.CrossRef

51.

Souverein D, Euser SM, Herpers BL, Hattink C, Houtman P, Popma A, et al. No nosocomial transmission under standard hygiene precautions in short term contact patients in case of an unexpected ESBL or Q&A E. coli positive patient: a one-year prospective cohort study within three regional hospitals. Antimicrob Resist Infect Control. 2017;6 Available from: http://aricjournal.biomedcentral.com/articles/10.1186/s13756-017-0228-6. [cited 2018 Oct 31].

52.

Zahar J-R, Poirel L, Dupont C, Fortineau N, Nassif X, Nordmann P. About the usefulness of contact precautions for carriers of extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis. 2015;15 Available from: http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-015-1244-x. [cited 2018 Oct 31].

53.

Zahar JR, Garrouste-Orgeas M, Vesin A, Schwebel C, Bonadona A, Philippart F, et al. Impact of contact isolation for multidrug-resistant organisms on the occurrence of medical errors and adverse events. Intensive Care Med. 2013;39:2153–60.CrossRef

54.

Morgan DJ, Diekema DJ, Sepkowitz K, Perencevich EN. Adverse outcomes associated with contact precautions: a review of the literature. Am J Infect Control. 2009;37:85–93.CrossRef

55.

Gurieva T, Dautzenberg MJD, Gniadkowski M, Derde LPG, Bonten MJM, Bootsma MCJ. The transmissibility of antibiotic-resistant Enterobacteriaceae in intensive care units. Clin Infect Dis. 2018;66:489–93.CrossRef

56.

Scheuerman O, Schechner V, Carmeli Y, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, et al. Comparison of predictors and mortality between bloodstream infections caused by ESBL-producing Escherichia coli and ESBL-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2018;39:660–7.CrossRef

57.

Freeman JT, Rubin J, McAuliffe GN, Peirano G, Roberts SA, Drinković D, et al. Differences in risk-factor profiles between patients with ESBL-producing Escherichia coli and Klebsiella pneumoniae: a multicentre case-case comparison study. Antimicrob Resist Infect Control. 2014;3:27.CrossRef

58.

Han JH, Bilker WB, Nachamkin I, Zaoutis TE, Coffin SE, Linkin DR, et al. The effect of a hospital-wide urine culture screening intervention on the incidence of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species. Infect Control Hosp Epidemiol. 2013;34:1160–6.CrossRef

59.

Djibré M, Fedun S, Le Guen P, Vimont S, Hafiani M, Fulgencio J-P, et al. Universal versus targeted additional contact precautions for multidrug-resistant organism carriage for patients admitted to an intensive care unit. Am J Infect Control. 2017;45:728–34.CrossRef

60.

Dananché C, Bénet T, Allaouchiche B, Hernu R, Argaud L, Dauwalder O, et al. Targeted screening for third-generation cephalosporin-resistant Enterobacteriaceae carriage among patients admitted to intensive care units: a quasi-experimental study. Crit Care. 2015;19:38.CrossRef

61.

Tschudin-Sutter S, Lucet J-C, Mutters NT, Tacconelli E, Zahar JR, Harbarth S. Contact precautions for preventing nosocomial transmission of extended-spectrum β lactamase–producing Escherichia coli: a point/counterpoint review. Clin Infect Dis. 2017;65:342–7.CrossRef

62.

Vodovar D, Marcadé G, Rousseau H, Raskine L, Vicaut E, Deye N, et al. Predictive factors for extended-spectrum beta-lactamase producing Enterobacteriaceae causing infection among intensive care unit patients with prior colonization. Infection. 2014;42:743–8.CrossRef

63.

Goulenok T, Ferroni A, Bille E, Lécuyer H, Join-Lambert O, Descamps P, et al. Risk factors for developing ESBL E. coli: can clinicians predict infection in patients with prior colonization? J Hosp Infect. 2013;84:294–9.CrossRef

64.

Gorrie CL, Mirčeta M, Wick RR, Edwards DJ, Thomson NR, Strugnell RA, et al. Gastrointestinal carriage is a major reservoir of Klebsiella pneumoniae infection in intensive care patients. Clin Infect Dis. 2017;65:208–15.CrossRef

65.

Sakellariou C, Gürntke S, Steinmetz I, Kohler C, Pfeifer Y, Gastmeier P, et al. Sepsis caused by extended-spectrum beta-lactamase (ESBL)-Positive K. pneumoniae and E. coli: comparison of severity of sepsis, delay of anti-infective therapy and ESBL genotype. Yam WC, editor. PLoS One. 2016;11:e0158039.CrossRef

66.

Falcone M, Vena A, Mezzatesta ML, Gona F, Caio C, Goldoni P, et al. Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae. Ann Ig Med Prev E Comunita. 2014;26:293–304.

67.

Joo E-J, Park DA, Lee NR, Moon S-Y, Choi J-K, Ko J-H, et al. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems. Eur J Clin Microbiol Infect Dis. 2017;36:2093–100.CrossRef

68.

Vogelaers D, De Bels D, Forêt F, Cran S, Gilbert E, Schoonheydt K, et al. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients. Int J Antimicrob Agents. 2010;35:375–81.CrossRef

69.

Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, et al. Effect of piperacillin-Tazobactam vs Meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320:984.CrossRef

70.

Prevel R, Berdaï D, Boyer A. Antibiotics for ceftriaxone-resistant Gram-negative bacterial bloodstream infections. JAMA. 2019;321:613.CrossRef

71.

Boucher A, Meybeck A, Patoz P, Valette M, Thellier D, Delannoy PY, et al. Alternatives to carbapenems in ventilator-associated pneumonia due to ESBL-producing Enterobacteriaceae. J Inf Secur. 2016;73:293–6.

72.

Torres A, Zhong N, Pachl J, Timsit J-F, Kollef M, Chen Z, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285–95.CrossRef

73.

Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949–56.CrossRef

74.

Timsit J-F, Pilmis B, Zahar J-R. How should we treat hospital-acquired and ventilator-associated pneumonia caused by extended-spectrum β-lactamase–producing Enterobacteriaceae? Semin Respir Crit Care Med. 2017;38:287–300.CrossRef

75.

Dautzenberg MJD, Bayjanov JR, Leverstein-van Hall MA, Muller AE, Gelinck LBS, Jansen CL, et al. Dynamics of colistin and tobramycin resistance among Enterobacter cloacae during prolonged use of selective decontamination of the digestive tract. Antimicrob Resist Infect Control. 2018;7:67.CrossRef

76.

Halaby T, Al Naiemi N, Kluytmans J, van der Palen J, Vandenbroucke-Grauls CMJE. Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. Antimicrob Agents Chemother. 2013;57:3224–9.CrossRef

77.

Al Naiemi N, Heddema ER, Bart A, de Jonge E, Vandenbroucke-Grauls CM, Savelkoul PHM, et al. Emergence of multidrug-resistant Gram-negative bacteria during selective decontamination of the digestive tract on an intensive care unit. J Antimicrob Chemother. 2006;58:853–6.CrossRef

78.

Huttner B, Haustein T, Uckay I, Renzi G, Stewardson A, Schaerrer D, et al. Decolonization of intestinal carriage of extended-spectrum -lactamase-producing Enterobacteriaceae with oral colistin and neomycin: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother. 2013; Available from: https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkt174. [cited 2018 Oct 31].

79.

Gosalbes MJ, Vázquez-Castellanos JF, Angebault C, Woerther P-L, Ruppé E, Ferrús ML, et al. Carriage of Enterobacteria producing extended-spectrum β-lactamases and composition of the gut microbiota in an Amerindian community. Antimicrob Agents Chemother. 2016;60:507–14.CrossRef

80.

Araos R, Tai AK, Snyder GM, Blaser MJ, D’Agata EMC. Predominance of Lactobacillus spp. among patients who do not acquire multidrug-resistant organisms. Clin Infect Dis. 2016;63:937–43.CrossRef

81.

Bilinski J, Grzesiowski P, Sorensen N, Madry K, Muszynski J, Robak K, et al. Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study. Clin Infect Dis. 2017;65:364–70.CrossRef

82.

Singh R, van Nood E, Nieuwdorp M, van Dam B, ten Berge IJM, Geerlings SE, et al. Donor feces infusion for eradication of extended Spectrum beta-lactamase producing Escherichia coli in a patient with end stage renal disease. Clin Microbiol Infect. 2014;20:O977–8.CrossRef

83.

Singh R, de Groot PF, Geerlings SE, Hodiamont CJ, Belzer C, Berge IJMT, et al. Fecal microbiota transplantation against intestinal colonization by extended spectrum beta-lactamase producing Enterobacteriaceae: a proof of principle study. BMC Res Notes. 2018;11:190.CrossRef

84.

Huttner BD, de Lastours V, Wassenberg M, Maharshak N, Mauris A, Galperine T, et al. A five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clin Microbiol Infect. 2019. https://doi.org/10.1016/j.cmi.2018.12.009.

85.

Ruppé E, Martin-Loeches I, Rouzé A, Levast B, Ferry T, Timsit J-F. What’s new in restoring the gut microbiota in ICU patients? Potential role of faecal microbiota transplantation. Clin Microbiol Infect. 2018;24:803–5.CrossRef

86.

Caballero S, Kim S, Carter RA, Leiner IM, Sušac B, Miller L, et al. Cooperating commensals restore colonization resistance to vancomycin-resistant enterococcus faecium. Cell Host Microbe. 2017;21:592–602 e4.CrossRef

87.

Piewngam P, Quiñones M, Thirakittiwatthana W, Yungyuen T, Otto M, Kiratisin P. Composition of the intestinal microbiota in extended-spectrum β-lactamase-producing Enterobacteriaceae carriers and non-carriers in Thailand. Int J Antimicrob Agents. 2018; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0924857918303686. [cited 2018 Dec 20].

Title: Is systematic fecal carriage screening of extended-spectrum beta-lactamase-producing Enterobacteriaceae still useful in intensive care unit: a systematic review
Authors: Renaud Prevel
Alexandre Boyer
Fatima M’Zali
Agnès Lasheras
Jean-Ralph Zahar
Anne-Marie Rogues
Didier Gruson
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Care
Carbapenem Antibiotic
Published in: Critical Care / Issue 1/2019
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-019-2460-3

At a glance: The STEP trials

Springer Medicine

Is systematic fecal carriage screening of extended-spectrum beta-lactamase-producing Enterobacteriaceae still useful in intensive care unit: a systematic review

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Combined assessment of ΔPCT and ΔCRP could increase the ability to differentiate candidemia from bacteremia

Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies

Flagellin attenuates experimental sepsis in a macrophage-dependent manner

Obesity inducing acute respiratory distress syndrome: we should choose the right population!

Are we really preventing lung collapse with APRV?

Capillary refill time variation induced by passive leg raising predicts capillary refill time response to volume expansion